Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Michel, G.
Right arrow Articles by Alberto, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michel, G.
Right arrow Articles by Alberto, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:369-370, 1994
© 1994 European Society for Medical Oncology

brief-report

Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer

G. Michel1,, S. Leyvraz1, J. Bauer1, M. Aapro2, R. Stahel3 and P. Alberto2

1Centre Pluridisciplinaire d'Oncologie, CHUV Lausanne
2Division d'Oncologie, Hôpital Cantonal Universitaire Geneva
3Universitätsspital, Onkologie Abteilung Zurich, Switzerland

Correspondence to: Genevíève Michel-Reymond, M.D., Centre Pluridisciplinaire d'Oncologie, CHUV, 1011 Lausanne, Switzerland

BACKGROUND:: Elderly patients are excluded from chemotherapy trials, even though they represent 25% of those with small cell lung cancer. An effective chemotherapy regimen with limited toxicity should be developed with the aim not only of increasing the survival of these patients, but also of improving their quality of life and their independance.

PATIENTS AND METHODS:: Twenty-four patients with a median age of 72 years and small-cell lung cancer (SCLC) were included in the trial. Chemotherapy consisted of a weekly intravenous regimen of Carboplatin 80 mg/m2 and Teniposide 80 mg/m2 administered on an outpatient basis.

RESULTS:: Eight patients had limited and 16 extensive disease. After a median of 12 chemotherapy courses (2–31) the overall response rate was 66.7% (95% Cl: 44.7–84.4), with 5 patients in complete and 11 in partial remission. The median overall survival was 33 weeks, with 4 patients alive at more than one year. Improvement of symptoms occurred in 86% of patients. Toxicity, mainly hematological, was moderate.

CONCLUSIONS:: Weekly Carboplatin and VM-26 is an effective and non-toxic regimen for elderly patients, leading to results similar to those obtained with a more intensive regimen in a younger age group.

carboplatin, elderly, small-cell lung cancer, teniposide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. Rossi, P. Maione, G. Colantuoni, C. Guerriero, C. Ferrara, F. Del Gaizo, D. Nicolella, and C. Gridelli
Treatment of Small Cell Lung Cancer in the Elderly
Oncologist, June 1, 2005; 10(6): 399 - 411.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Neubauer, J. Schwartz, J. Caracandas, P. Conkling, D. Ilegbodu, T. Tuttle, and L. Asmar
Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age >= 70 Years
J. Clin. Oncol., May 15, 2004; 22(10): 1872 - 1877.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.